Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some
block the ability of cancer cells to grow and spread. Others find cancer cells and help kill
them or deliver cancer-killing substances to them. Drugs used in chemotherapy work in
different ways to stop tumor cells from dividing so they stop growing or die. Radiation
therapy uses high-energy x-rays to damage tumor cells. Combining monoclonal antibody therapy
with chemotherapy and radiation therapy may be an effective treatment for head and neck
cancer. This phase I trial is to see if combining bevacizumab, fluorouracil, and hydroxyurea
with radiation therapy works in treating patients who have advanced head and neck cancer